New data reveal how Bayer's asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes
The full picture of how Bayer's factor XIa inhibitor asundexian showed "inferior efficacy" compared to Eliquis has come into ...
Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million ...
A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a ...
Many microbes are extremophiles, capable of surviving conditions that would spell instant death for you and me. | Many ...
The FDA has approved a new type of stent designed specifically for infants and young children—including neonates born with ...
ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. | ReNeuron has joined the long list of ...
Cell engineering biotech Sana Biotechnology is bringing Dhaval Patel, M.D., Ph.D., on board as its first ever chief ...
The Roche subsidiary will lay off 93 employees in South San Francisco starting in early October, according to a Worker ...
In 2022, on the alpine shores of Lake Maggiore in northern Italy, longtime friends Samuel Bakhoum, M.D., Ph.D. and Stefano ...
Amid a yearslong clinical trial decline in the United Kingdom, a new public-private partnership has emerged in efforts to ...
The FDA’s Center for Drug Evaluation and Research (CDER) is consolidating its artificial-intelligence-related activities ...
Four months after Chinese gene editing company YolTech Therapeutics took its cholesterol disease-focused candidate into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results